Miranda Broz
University of California, San Francisco
13 Papers
4 Citations
Miranda Broz is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Tumor microenvironment & Immunotherapy. The author has an hindex of 7, co-authored 10 publications.
Chat about Author
Papers
Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity
Miranda Broz,Mikhail Binnewies,Bijan Boldajipour,Amanda E. Nelson,Joshua L. Pollack,David J. Erle,Andrea J. Barczak,Michael Rosenblum,Adil Daud,Diane L. Barber,Sebastian Amigorena,Laura J. van't Veer,Anne I. Sperling,Denise M. Wolf,Matthew F. Krummel +14 more
TL;DR: Across multiple mouse tumor models and human tumor biopsies, the intratumoral dendritic cell (DC) populations are delineated as distinct from macrophage populations, and CD103(+) DCs are extremely sparse and yet remarkably capable CTL stimulators.
1K
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments.
Kevin C. Barry,Joy Hsu,Miranda Broz,Francisco J. Cueto,Francisco J. Cueto,Francisco J. Cueto,Mikhail Binnewies,Alexis J. Combes,Amanda E. Nelson,Kimberly Loo,Raj Kumar,Michael Rosenblum,Michael Alvarado,Denise M. Wolf,Dusan Bogunovic,Nina Bhardwaj,Adil Daud,Patrick K. Ha,William R. Ryan,Joshua L. Pollack,Bushra Samad,Saurabh Asthana,Vincent Chan,Matthew F. Krummel +23 more
TL;DR: The studies reveal that innate immune SDCs and NK cells cluster together as an excellent prognostic tool for T cell–directed immunotherapy and that these innate cells are necessary for enhanced T cell tumor responses, suggesting this axis as a target for new therapies.
866
Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma
Edward W. Roberts,Miranda Broz,Mikhail Binnewies,Mark B. Headley,Amanda E. Nelson,Denise M. Wolf,Tsuneyasu Kaisho,Dusan Bogunovic,Nina Bhardwaj,Matthew F. Krummel +9 more
TL;DR: This work identifies an ongoing pathway to T cell priming, which should be harnessed for tumor therapies, and CCR7 expression levels in human tumors correlate with signatures of CD141(+) DC, intratumoral T cells, and better clinical outcomes.
853
α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas.
Eswari Dodagatta-Marri,Dominique S. Meyer,Melissa Reeves,R. Paniagua,Minh D. To,Mikhail Binnewies,Miranda Broz,Hidetoshi Mori,Di Wu,M. Adoumie,R. del Rosario,O. Li,T. Buchmann,B. Liang,Julia Malato,F. Arce Vargus,D. Sheppard,Byron Hann,A. Mirza,Sergio A. Quezada,Michael Rosenblum,Matthew F. Krummel,Allan Balmain,Rosemary J. Akhurst +23 more
TL;DR: It is shown that α-PD-1 not only initiates a tumor rejection program, but can induce a competing TGFβ-driven immuno-suppressive program, which identifies new opportunities for α- PD-1/α-TGFβ combinatorial treatment of SCCs especially those with a high mutation load, high CD4+ T cell content and pSmad3 signaling.
Antitumor adaptive immunity remains intact following inhibition of autophagy and antimalarial treatment
Hanna Starobinets,Jordan Ye,Miranda Broz,Kevin C. Barry,Juliet Goldsmith,Timothy Marsh,Fanya Rostker,Matthew F. Krummel,Jayanta Debnath +8 more
TL;DR: It is demonstrated that antitumor adaptive immunity is not adversely impaired by autophagy inhibition in immune-competent mouse models of melanoma and mammary cancer, allowing for the future possibility of combining Autophagy inhibitors with immunotherapy in certain clinical contexts.